Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beyond Air, Inc. (NASDAQ: XAIR) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, giving investors structured access to official information about this commercial-stage medical device and biopharmaceutical issuer. Beyond Air develops nitric oxide (NO) generators and delivery systems, including the LungFit platform, and pursues NO-based therapeutics in respiratory, neurological, and oncology indications. Its filings provide detailed context on these activities.
Core documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically describe the LungFit PH system, its FDA approval and CE Mark for neonatal hypoxic respiratory failure associated with pulmonary hypertension, the broader LungFit pipeline for severe lung infections, and affiliated programs like Beyond Cancer’s ultra-high concentration NO for solid tumors and NeuroNOS’s small-molecule nNOS inhibitors. Risk factors, R&D narratives, and segment information in these reports help readers understand the company’s NO-focused strategy and development stage.
Current reports on Form 8-K capture material events, including financing agreements such as promissory notes and equity purchase arrangements, warrant inducement transactions, reverse stock split implementation, leadership changes, and transactions involving subsidiaries like NeuroNOS. Registration statements, including Forms S-1 or S-3, outline the terms of securities offerings, equity lines of credit, and resale arrangements for investors like Streeterville Capital.
On this page, Stock Titan supplements raw filings data with AI-powered summaries that highlight key terms, financial obligations, and business implications from lengthy documents. Users can quickly identify items related to capital structure changes, Orphan Drug Designations, or regulatory milestones without reading every page. Real-time updates from EDGAR, combined with structured access to Forms 4 and other ownership reports, allow close monitoring of insider and institutional activity in XAIR. This makes the filings page a practical starting point for due diligence on Beyond Air’s regulatory, financial, and clinical disclosure record.
Alyeska Investment Group and affiliates report a 7.27% stake in Beyond Air, Inc. common stock as of December 31, 2025. They beneficially own 582,638 shares, with no sole voting or dispositive power and full authority shared among the reporting persons.
The holding consists of 224,193 shares of common stock and 358,445 PIPE shares, based on 8,009,488 shares of common stock outstanding cited from a December 16, 2025 prospectus. The group states the position is held in the ordinary course of business and not for influencing control.
Balyasny-affiliated investment entities have disclosed a significant passive stake in Beyond Air, Inc. They report beneficial ownership of 763,266 shares of common stock, including 299,104 shares issuable upon exercise of warrants, representing approximately 9.53% of Beyond Air’s outstanding common shares.
The shares are held by Atlas Diversified Master Fund, Ltd., for which Balyasny Asset Management L.P. acts as investment manager. Related entities GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and individual Dmitry Balyasny may be deemed to share voting and investment power. The warrants are subject to a 9.99% beneficial ownership blocker, limiting exercises that would push ownership above that level. The reporting parties certify that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Beyond Air.
Beyond Air, Inc. reported fiscal third-quarter 2026 revenue of $2.2 million, up 105% from $1.1 million a year earlier, driven by growing adoption of its LungFit PH nitric oxide system in the U.S. and abroad. Gross profit improved to $0.3 million from a gross loss of $0.2 million.
Operating costs declined, with research and development down to $2.4 million and selling, general and administrative expenses reduced to $4.5 million. Net loss attributable to common stockholders narrowed to $7.3 million, or $0.85 per share, compared with a $13.0 million loss, or $2.96 per share, in the prior-year quarter.
The company ended the quarter with $17.8 million in cash, cash equivalents, restricted cash and marketable securities, plus $4.5 million of net proceeds from a subsequent private placement, and believes this supports a cash runway into calendar 2027. It maintained fiscal 2026 revenue guidance of $8–10 million and reported total long-term debt of $22.0 million.
Beyond Air highlighted commercial milestones, including its first LungFit PH sale to a VA Medical Center and international distribution now covering 40 countries. It also noted a binding agreement under which XTL Biopharmaceuticals will acquire 85% of NeuroNOS, with Beyond Air eligible for $1.0 million in cash, up to $31.5 million in milestones, and 19.9% equity in XTL.
Beyond Air, Inc. reported higher revenue but continuing losses for the quarter ended December 31, 2025. Revenue rose to $2.2 million from $1.1 million a year earlier, driven mainly by LungFit PH lease revenue, yet gross profit was only $0.3 million as costs remained high.
The company posted a quarterly net loss attributable to Beyond Air of $7.3 million, versus $13.0 million a year prior, and a nine‑month net loss of $23.0 million. Operating cash use for the nine months was $13.2 million. As of December 31, 2025, cash, cash equivalents, marketable securities and restricted cash totaled $17.8 million, with an accumulated deficit of $309.3 million and long‑term debt of $22.0 million.
Management states that these factors raise “substantial doubt” about the ability to meet obligations without new capital and concluded additional funding will be required within one year of issuance of these statements. To bolster liquidity, the company issued an $11.5 million secured loan and a $12.0 million secured promissory note in late 2024 and 2025, and completed a $5.0 million private placement on January 16, 2026. Beyond Air also gained a European CE mark for LungFit PH in November 2024 and effected a 1‑for‑20 reverse stock split in July 2025. Shares outstanding were 10,529,344 as of February 10, 2026.
Beyond Air, Inc. has filed a prospectus covering the resale of 524,990 shares of common stock, 3,405,828 shares issuable upon exercise of pre-funded warrants, and 3,930,818 shares issuable upon exercise of common warrants by existing investors. The company will not receive proceeds from these resales, but could receive cash if the warrants are exercised. Shares outstanding were 10,529,344 as of January 22, 2026, rising to 17,865,990 assuming full warrant exercise. Recent developments include a $12.05 million secured note at 15% interest, a $20 million equity purchase agreement with Streeterville Capital, expanded credit from insider lenders, and a binding letter of intent to sell its 85% stake in NeuroNOS Ltd. for cash, XTL Biopharmaceuticals equity, and up to $31.5 million in milestones. LungFit PH has also received European CE mark approval, broadening its approved indications beyond the United States.
Beyond Air, Inc. reported voting results from its 2026 Annual Meeting of Stockholders. Out of 8,009,488 shares outstanding as of December 3, 2025, a quorum of 4,221,408 shares, or 52.70%, was represented in person or by proxy.
Stockholders elected six directors to serve until the next annual meeting or until their successors are qualified. They also ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending March 31, 2026.
In addition, stockholders approved the Eighth Amended and Restated 2013 Equity Incentive Plan, increasing shares reserved for issuance by 850,000, and approved the option to adjourn the meeting, although adjournment was not needed because all key proposals passed.
Beyond Air, Inc. has filed an S-3 shelf registration to allow existing investors to resell common stock and shares issuable from previously issued warrants. The filing covers 524,990 outstanding common shares, plus additional shares issuable from pre-funded warrants and common warrants.
The pre-funded warrants are exercisable at $0.0001 per share, and the common warrants are exercisable at $1.147 per share through January 16, 2031. Beyond Air will not receive proceeds from stockholder resales, but would receive cash if holders exercise these warrants. Shares outstanding were 10,529,344 as of January 22, 2026, and would be 17,865,990 if all warrant shares in this filing are issued.
Beyond Air, Inc. entered into a private placement with an institutional investor, agreeing to sell 524,990 common shares at
Beyond Air, Inc. reported that XTL Biopharmaceuticals Ltd. has signed a binding letter of intent to acquire Beyond Air’s 85% ownership interest in NeuroNOS Ltd., a biotechnology company developing disease‑modifying therapeutics for Autism Spectrum Disorder and neuro‑oncology. Under the proposed terms, Beyond Air would receive 19.9% of XTL’s issued share capital, $1 million in cash, and milestone-based contingent payments of up to $31.5 million.
The companies are working to finalize definitive agreements for the transaction, which are expected to be filed in a future current report or in Beyond Air’s Annual Report on Form 10‑K. The disclosure emphasizes that these statements are forward‑looking and may differ from actual results.